Until law, GLP-1 drugs were used to treat diabetes, obesity and even the recent evidences suggest that it could as well be used to treat chronic kidney problems. There is yet another research, published in JAMA Psychiatry on February 25, titled Once-Weekly Semaglutide in Adults With Alcohol Use Disorder: A Randomized Clinical Trial that explores if GLP-1 receptor agonist semaglutide reduce alcohol consumption and cravings in adults with alcohol use disorder.

What Do Studies Say?

The research was conducted over a period of 9 weeks, where in the randomized clinical trial, the participants who were administered semaglutide, it led to reductions in some but not all measures of weekly consumptions. It also reduced weekly alcohol and craving related to placebo, and also led to a greater relative reduction in cigarettes per day.

The research also found that weekly injections of semaglutide, which is the active ingredient in weight loss drugs like Wegovy also helped reduce cravings in people with alcohol use disorder.

The lead author Christian Hendershot said that these findings will help in developing new approaches to treat alcoholism. "Two drugs currently approved to reduce alcohol consumption aren't widely used. The popularity of Ozempic and other GLP-1 receptor agonists increases the chances of broad adoption of these treatments for alcohol use disorder," said Hendershot in news release by the University of Southern California's Institute for Addiction Research, where he is the director.

The study is government-funded research and was funded by the National Institute on Alcohol Abuse and Alcoholism, part of the National Institutes of Health.

How Was The Study Conducted?

The study was small, and took in account for only 48 adults over two months, thus experts say that it is not yet clear how safe these drugs are for people who do not need to lose weight. Though the results do add up with the evidence form animal studies on drugs like Ozempic and Wegovy on how it helps manage cravings, not just for food, but also for tobacco and alcohol. Scientists are also studying these drugs on smokers, people with opioid addiction and cocaine users.

Co-author Dr Klara Klein of the University of North Carolina at Chapel Hill who treats people with obesity and diabetes said, "This is such promising data. And we need more of it. We frequently will hear that once people start these medications that their desire to drink is very reduced, if not completely abolished."

Why Does It Work So Well Against Alcoholism?

The GLP-1 receptor agonists work by mimicking hormones GLP-1 in the gut and brain that regulates appetite and feelings of fullness. This response is what helps one lose weight, and what helps one curb their craving for alcohol. These drugs that mimic the functioning of your brain, which is responsible to tell your body when to stop consuming, are the same hormones that tell your body about other kinds of consumptions, including alcohol. Therefore by consuming the weight loss drugs one can treat alcohol use disorder.

However, the researchers have pointed out on the limited data on the research and have suggested to continue using the three approved drugs by the National Institute on Alcohol Abuse and Alcoholism and Substance Abuse and Mental Health Services Administration, namely, Disulfiram, Naltrexone, and Acamprosate to treat alcohol use disorder until large studies confirm these findings.

The recent rise in COVID-19 cases and deaths in Andhra Pradesh has renewed concerns over the virus, prompting neighbouring states such as Tamil Nadu and Odisha to step up surveillance. Andhra Pradesh has reported three COVID-related deaths along with several active cases.

However, health experts say the current situation does not indicate a major public health threat and have urged people to focus on prevention rather than panic.

Tamil Nadu's Health Department has also clarified that there is no evidence of a highly virulent COVID-19 variant circulating in the state. Officials noted that current COVID-19 infections remain lower than in previous years.

Virus Continues To Evolve

Also read: Omicron Sub-Lineages Likely Behind COVID Surge In India: Why Deaths Are Occurring

"The SARS-CoV-2 virus never truly disappears; it continues to resurface through new mutations. Viral strains naturally mutate as part of their evolution, making viral illnesses highly dynamic," Dr Abha Mashur, Pulmonologist at Lilavati Hospital and Research Centre, Mumbai, told HealthandMe.

She said the key concern is not the emergence of new variants, but the severity of disease they cause.

"At present, we are predominantly seeing upper respiratory involvement and milder cases of viral illness," said Dr Mashur, adding that Lilavati Hospital has admitted only one or two COVID-19 patients recently, all of whom required monitoring but experienced only mild illness.

Who Is At Higher Risk?

While most infections are mild, experts caution that certain groups remain vulnerable to severe disease. These include:

• Elderly individuals
• Pregnant women
• People with chronic heart disease
• Patients with COPD or interstitial lung disease (ILD)
• Those with chronic kidney or liver disease
• Immunocompromised individuals.

Read More: 13.5 Million Children Remain Zero-Dose In 2025 Despite Global Vaccination Gains: UN Report

Omicron Subvariants Circulating In India

According to Dr Mashur, the current wave is being driven by Omicron subvariants — the JN.1 variant and the BA.3.2 variant — that remain highly transmissible but are not causing severe illness in most people.

JN.1: The expert explained that the JN.1 variant is highly transmissible and possesses enhanced immune-evasion capabilities, allowing it to partially bypass immunity from previous infection or vaccination. However, she said it continues to cause predominantly mild illness compared to earlier variants.

BA.3.2: The BA.3.2 variant has accumulated a large number of mutations, raising concerns about immune escape. Despite this, available evidence suggests it has not led to more severe disease and is not currently considered a cause for alarm.

No Need for Panic

The experts stressed that the current rise in cases should encourage vigilance rather than fear. Vaccination, masking in high-risk settings, and early medical consultation remain the most effective tools to reduce transmission and protect vulnerable populations.

"The current situation should not create panic, but should prompt people to seek medical attention early. Those who develop symptoms of a viral infection should avoid public spaces and consult a doctor promptly so that transmission can be curtailed at the earliest," Dr Mashur said.

Dr Neha Rastogi, Senior Consultant, Infectious Diseases, Fortis Memorial Research Institute, Gurugram, urged people to continue following basic preventive measures.

"To reduce the risk of infection, people should stay up to date with COVID-19 vaccinations, wear masks in crowded indoor settings, maintain hand hygiene, ensure good ventilation, and avoid close contact when unwell. Anyone experiencing symptoms such as fever, cough, or breathlessness should get tested and seek timely medical advice."

The debate around the effects of late-night eating on metabolism and overall fitness is not new. A new study has found a strong link between night owls’ time of eating and their metabolic health.

The study observes that those who stayed late at night tend to have poor metabolic health and effectively more body fat than those who didn’t, as they tend to have the lion’s share of their calories in the later part of the day.

How Was The Study Conducted?

The study examines an important area of nutrition called chrononutrition, which basically refers to how the time of eating affects the body’s circadian rhythm. It investigated how chronotype is associated with dietary intake, meal timing, body composition, and metabolic health.

Published in Frontiers in Nutrition, the study observed 287 healthy women aged 18 to 45 from New Zealand. Their food intake was studied for five days along with their meal timings.

Participants were classified as morning, intermediate, or evening chronotypes using a validated questionnaire. They also recorded everything they ate and drank over five days.

Researchers studied body composition using dual-energy X-ray absorptiometry (DXA), a highly accurate method for measuring body fat, and analyzed metabolic markers including glucose, insulin, cholesterol, and triglycerides.

Also read: India Gets Its First Plant-Based Vitamin D3: What You Need to Know

What Did The Study Find?

The study found that women with an evening chronotype had higher body mass index (BMI), a higher percentage of body fat, and more abdominal fat compared with morning and intermediate chronotypes.

Interestingly, these differences were observed even though total daily calorie intake did not significantly differ between the groups.

The study also found that rather than eating more food overall, evening chronotypes tended to delay their meals and consumed a larger proportion of their daily calories later in the day.

The findings indicate that when people eat may play an important role in metabolic health along with what and how much they eat.

The researchers wrote, “Our findings indicate that women with a later chronotype tend to have higher body fat and consume a greater proportion of their energy intake later in the day.”

Also read: Why Sustainable Weight Loss Requires More Than Cutting Calories

Why Meal Timings Affect Your Metabolism?

Although the current study directly does not determine whether late eating directly causes higher body fat, it observes a pattern that chronotype and meal timing are important factors to consider in order to achieve a better fitness level.

The body's internal clock is responsible for regulating many metabolic processes, including blood sugar control, insulin sensitivity, and digestion, among others. Late night eating not only interferes with insulin sensitivity but also impairs your metabolic health.

Research has repeatedly shown that these processes function a lot more efficiently earlier in the day. Eating a large proportion of daily calories late in the evening is therefore less favorable for metabolism as it can lead to increased fat accumulation over time.

With time, those with evening chronotype are at a greater risk of obesity and obesity-related chronic lifestyle disorders like hypertension, diabetes, high cholesterol, heart disease, and more.

Global childhood vaccination coverage improved in 2025, but 13.5 million children still did not receive a single vaccine in their first year of life, leaving them vulnerable to preventable diseases, according to the latest WHO-UNICEF Estimates of National Immunization Coverage (WUENIC).

The report found that 85% of children worldwide (about 110 million) completed the recommended three-dose diphtheria, tetanus and pertussis (DTP) vaccine series, while 90% of infants (nearly 116 million) received at least one dose of the DTP vaccine.

Although the number of zero-dose children declined by nearly 750,000 compared to 2024, WHO and UNICEF said progress remains uneven.

"Every child, whether born into wealth or poverty, peace or conflict, deserves the life-saving protection that vaccines provide," said Dr Tedros Adhanom Ghebreyesus, WHO Director-General.

Measles Vaccination Still Below Target

The report highlights persistent gaps in measles immunization. An estimated 7.3 million infants received their first DTP dose but missed their first measles-containing vaccine (MCV1). Global measles coverage remains below the 95% threshold needed to prevent outbreaks:

• 84% received the first measles dose (MCV1)
• 77% received the second dose (MCV2)

The recent measles outbreaks in Bangladesh and the US, underscoring how immunity gaps can quickly lead to disease resurgence.

As per the latest data, Bangladesh’s combined tally of confirmed and suspected measles-related deaths stands at 766, while the cumulative number of suspected cases nationwide stands at 113,244.

The US is also experiencing a major measles resurgence, reporting over 2,231 confirmed cases across 42 jurisdictions. This puts the country on track to surpass 2025's total (2,289 cases), which was the highest in decades, threatening the nation's measles elimination status.

"These outbreaks underscore how quickly immunity gaps can lead to the resurgence and spread of this highly infectious disease," said Dr Catharina Boehme, Officer-in-Charge, WHO South-East Asia Region.

Also read: England Confirms Third Measles Death: NHS Launches Catch-Up MMRV Vaccination Drive

Conflict and Poverty Leave Millions Unprotected

More than half of all zero-dose children live in fragile, conflict-affected or vulnerable settings, despite these countries accounting for only about one-third of the world's child population.

Immunization programs in these regions continue to face disruptions due to conflict, political instability, displacement and chronic underfunding.

UNICEF Executive Director Catherine Russell said that while vaccination rates have rebounded from the declines seen during the COVID-19 pandemic, millions of children remain unreached.

"Millions of vulnerable children are still being left unprotected due to conflict, displacement and poverty. No child should suffer from a disease that a simple vaccine can prevent."

Regional Progress Remains Uneven

The report based on data from 195 countries shows mixed progress since 2019:

• 100 countries have maintained at least 90% DTP3 coverage.
• 30 countries improved vaccination coverage after falling below the 90% mark before the pandemic.
• 65 countries continue to stagnate or decline, including 13 fragile or conflict-affected nations.
• The Americas and South-East Asia have recovered to or exceeded pre-pandemic vaccination levels, with South-East Asia emerging as the best-performing WHO region.
• Africa, Europe and the Eastern Mediterranean have improved but remain below 2019 levels, while the Western Pacific continues to lag behind its pre-pandemic baseline.

Funding Cuts Threaten Progress

WHO and UNICEF warned that reductions in international health funding could slow or reverse recent gains. The agencies called on governments and partners to:

• Strengthen immunization services in fragile and conflict-affected settings.
• Counter vaccine misinformation and improve public confidence.
• Increase domestic and international funding for immunization programs.
• Invest in stronger disease surveillance and immunization data systems.